8 citations
,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.
February 2026 in “Postgraduate Medicine” 5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
8 citations
,
March 2002 in “Archiv Der Pharmazie” The compound 4c effectively inhibits the enzyme linked to hair loss.
45 citations
,
February 2005 in “Steroids” Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
4 citations
,
September 2010 in “Medical Hypotheses”
3 citations
,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
October 2017 in “The Journal of Urology” 5α-Reductase inhibitors can negatively impact sexual function.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
1 citations
,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
17 citations
,
June 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
39 citations
,
February 2011 in “The Prostate/The prostate” Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
9 citations
,
April 2020 in “The Journal of Urology” 5α-Reductase inhibitors don't cause depression.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
5α-reductase inhibitors are effective for treating hair loss in androgenetic alopecia.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
June 2021 in “F1000Research” Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.
July 2025 in “Journal of Investigative Dermatology”
October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
30 citations
,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
108 citations
,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
28 citations
,
May 1986 in “Clinics in endocrinology and metabolism” New compounds may soon be tested to treat excessive hair growth in women.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
72 citations
,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
Eriocitrin and silymarin might be effective for hair loss treatment and need more research.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.